New approaches in the use of selegiline for the treatment of Parkinson's disease.
作者： A. J. Lees , J. Frankel , V. Eatough , G. M. Stern
DOI: 10.1111/J.1600-0404.1989.TB01793.X
关键词:
摘要: – Selegiline hydrochloride (deprenyl) is a safe, useful adjuvant therapy in patients with Parkinson's disease treated L-dopa. The optimum time for its introduction into the treatment regimen of patient remains controversial. A multi-centre long-term study being conducted by Disease Research Group United Kingdom to attempt answer whether selegiline improves natural history discussed. In separate we have been unable demonstrate that higher doses (up 40 mg day) produce additional therapeutic benefit above conventional dose 10 day levodopa-treated motor fluctuations. Preliminary data from neuropsychological also presented which suggests may beneficial effects on speed psychomotor responses supporting anecdotal clinical observations increased mental energy and alacrity.
sci-hub.se 参考文章(11)
O Rascol, JL Montastruc, JM Senard, JF Demonet, M Simonetta, A Rascol, None, Two weeks of treatment with deprenyl (selegiline) does not prolong l‐dopa effect in parkinsonian patients A double‐blind cross‐over placebo‐controlled trial Neurology. ,vol. 38, pp. 1387- 1387 ,(1988) , 10.1212/WNL.38.9.1387
D. ROGERS, A. J. LEES, EILEEN SMITH, M. TRIMBLE, G. M. STERN, Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness. An experimental study. Brain. ,vol. 110, pp. 761- 776 ,(1987) , 10.1093/BRAIN/110.3.761
John Mann, Samuel Gershon, L-deprenyl, a selective monoamine oxidase type-b inhibitor in endogenous depression Life Sciences. ,vol. 26, pp. 877- 882 ,(1980) , 10.1016/0024-3205(80)90350-1
J. Fowler, R. MacGregor, A. Wolf, C. Arnett, S. Dewey, D Schlyer, D Christman, J Logan, M Smith, H Sachs, e. al., Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. Science. ,vol. 235, pp. 481- 485 ,(1987) , 10.1126/SCIENCE.3099392
Lawrence I. Golbe, Abraham N. Lieberman, Manfred D. Muenter, J. Eric Ahlskog, Govindan Gopinathan, Andreas N. Neophytides, Sun-Hoo Foo, Roger C. Duvoisin, Deprenyl in the Treatment of Symptom Fluctuations in Advanced Parkinson's Disease Clinical Neuropharmacology. ,vol. 11, pp. 45- 55 ,(1988) , 10.1097/00002826-198802000-00004
W. Birkmayer, J. Knoll, P. Riederer, M. B. H. Youdim, Vera Hars, J. Marton, Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. Journal of Neural Transmission. ,vol. 64, pp. 113- 127 ,(1985) , 10.1007/BF01245973
W. A. Lishman, Selective factors in memory. Part 2: affective disorder Psychological Medicine. ,vol. 2, pp. 248- 253 ,(1972) , 10.1017/S0033291700042549
M Schachter, C D Marsden, J D Parkes, P Jenner, B Testa, Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa. Journal of Neurology, Neurosurgery, and Psychiatry. ,vol. 43, pp. 1016- 1021 ,(1980) , 10.1136/JNNP.43.11.1016
A.J. Lees, L.J. Kohout, K.M. Shaw, G.M. Stern, J.D. Elsworth, M. Sandler, M.B.H. Youdim, DEPRENYL IN PARKINSON'S DISEASE The Lancet. ,vol. 310, pp. 791- 795 ,(1977) , 10.1016/S0140-6736(77)90725-5
Peter Riederer, Moussa B. H. Youdim, Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. Journal of Neurochemistry. ,vol. 46, pp. 1359- 1365 ,(1986) , 10.1111/J.1471-4159.1986.TB01747.X